Bernstein Maintains Outperform on Medtronic, Lowers Price Target to $97

Benzinga Newsdesk www.benzinga.com Negative 93.4%

Neg 93.4% Neu 0% Pos 0%

Bernstein analyst Lee Hambright maintains Medtronic (NYSE:MDT) with a Outperform and lowers the price target from $112 to $97.